{
    "eid": "2-s2.0-85078006467",
    "title": "Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action",
    "cover-date": "2020-03-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Clinical Biochemistry",
            "@code": "1308",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "Antibody drug conjugate",
        "Bispecific antibody",
        "Monoclonal antibody",
        "Multiple myeloma"
    ],
    "authors": [
        "Kitsada Wudhikarn",
        "Beatriz Wills",
        "Alexander M. Lesokhin"
    ],
    "citedby-count": 26,
    "ref-count": 66,
    "ref-list": [
        "Cancer statistics",
        "Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma",
        "Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma",
        "Targeting CD38 with daratumumab monotherapy in multiple myeloma",
        "Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial",
        "Daratumumab, lenalidomide, and dexamethasone for multiple myeloma",
        "Daratumumab, bortezomib, and dexamethasone for multiple myeloma",
        "Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma",
        "Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): a multicenter, randomized, phase 3 study (APOLLO)",
        "Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma",
        "Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (RRMM): primary analysis results from the randomized, open-label, phase 3 study candor (NCT03158688)",
        "Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma",
        "Daratumumab plus lenalidomide and dexamethasone for untreated myeloma",
        "Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study",
        "Immunotherapy in multiple myeloma: accelerating on the path to the patient",
        "Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma",
        "A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma",
        "A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma",
        "Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study",
        "Phase III (IMROZ) study design: isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM)",
        "f",
        "A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma",
        "Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study",
        "Elotuzumab therapy for relapsed or refractory multiple myeloma",
        "Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma",
        "Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM",
        "Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival",
        "The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies",
        "A phase 1 study in subjects with relapsed or refractory multiple myeloma",
        "MEDI2228, a novel BCMA pyrrolobenzodiazepine antibody drug conjugate, overcomes drug resistance and synergizes with bortezomib and DNA damage response inhibitors in multiple myeloma",
        "Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial",
        "Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study",
        "Investigational antibody-drug conjugates for treatment of B-lineage malignancies",
        "Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma",
        "Indatuximab ravtansine (BT062) monotherapy in patients with relapsed and/or refractory multiple myeloma",
        "Indatuximab ravtansine (BT062) in combination with low-dose dexamethasone and lenalidomide or pomalidomide: clinical activity in patients with relapsed/refractory multiple myeloma",
        "Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma",
        "Bispecific antibodies",
        "Bispecific antibodies: a mechanistic review of the pipeline",
        "Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment",
        "Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma",
        "Anti-BCMA BiTE\u00ae AMG 701 potently induces specific T cell lysis of human multiple myeloma (MM) cells and immunomodulation in the bone marrow microenvironment",
        "A phase I, open-label study to evaluate the safety, pharmacokinetic, pharmacodynamic, and clinical activity of PF-06863135, a B-cell maturation antigen/CD3 bispecific antibody, in patients with relapsed/refractory advanced multiple myeloma",
        "Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy",
        "A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo",
        "Monoclonal antibodies for the treatment of multiple myeloma: an update",
        "Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: updated results of a first-in-human (FIH) phase I dose escalation study",
        "Preclinical characterization of AFM26, a novel B cell maturation antigen (BCMA)-Directed tetravalent bispecific antibody for high affinity retargeting of NK cells against myeloma",
        "Trispecific antibodies for selective CD16A-directed NK-cell engagement in multiple myeloma",
        "Anti-GPRC5D/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma",
        "A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma",
        "Targeting multiple myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release",
        "Immunotherapy with long-lived anti-CD38 \u00d7 anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human myeloma cell lines and CD38+ cells in monkeys: a potential therapy for multiple myeloma",
        "Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma",
        "Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation",
        "A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo",
        "Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma",
        "Anti-FcRH5/CD3 T cell dependent bispecific antibody (TDB) for the treatment of multiple myeloma",
        "Immunophenotype of normal and myelomatous plasma-cell subsets",
        "Treatment with AMG 420, an anti-B-cell maturation antigen (BCMA) bispecific T-cell engager (BiTE\u00ae) antibody construct, induces minimal residual disease (MRD) negative complete responses in relapsed and/or refractory (R/R) multiple myeloma (MM) patients: results of a first-in-human (FIH) phase I dose escalation study",
        "Resistance to proteasome inhibitors and other targeted therapies in myeloma",
        "Myeloma escape from immunity: an \u201cinside\u201d job",
        "Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma",
        "The emerging role of upfront monoclonal antibodies for multiple Myeloma2019"
    ],
    "affiliation": [
        {
            "affiliation-city": "New York",
            "@id": "60009343",
            "affilname": "Memorial Sloan-Kettering Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "New York",
            "@id": "60019868",
            "affilname": "Weill Cornell Medical Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60019868",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "Core",
        "Memorial Sloan Kettering Cancer Center",
        "Parker Institute for Cancer Immunotherapy"
    ]
}